{"id":998107,"date":"2026-08-26T07:06:14","date_gmt":"2026-08-26T11:06:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/"},"modified":"2026-08-26T07:06:14","modified_gmt":"2026-08-26T11:06:14","slug":"definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/","title":{"rendered":"Definium Therapeutics to Participate at Upcoming Investor Conferences and Events"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistcircle { list-style-type: circle }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Definium Therapeutics to Participate at Upcoming Investor Conferences and Events<\/b><\/p>\n<p>NEW YORK&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nDefinium Therapeutics, Inc. (Nasdaq: DFTX) (&#8220;Definium&#8221; or the &#8220;Company&#8221;), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company\u2019s management team will participate in the following investor conferences and events:<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Stifel Hosted Webinar: Definium Therapeutics Virtual Fireside Chat<\/b>\n<ul class=\"bwlistcircle\">\n<li>\nPresentation Date and Time: Tuesday, September 1, 2026 at 1:00 PM ET<\/p>\n<\/li>\n<li>\nModerator: Paul Matteis, Head of Therapeutics Research<\/p>\n<\/li>\n<li>\nFocus: Discussion of Definium\u2019s positive topline results from the Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder (GAD), including key clinical takeaways and implications for the program, as well as expectations for the upcoming Phase 3 Panorama topline results, the second pivotal study of DT120 ODT in GAD.<\/p>\n<\/li>\n<li>\nWebcast Link: <i>Please contact your Stifel representative for access to the fireside chat<\/p>\n<p><\/i><\/li>\n<\/ul>\n<\/li>\n<li><b>TD Cowen 6<sup>th<\/sup> Annual Novel Mechanisms in Neuropsychiatry Summit<\/b>\n<ul class=\"bwlistcircle\">\n<li>\nPresentation Date and Time: Wednesday, September 23, 2026 at 9:30 AM ET<\/p>\n<\/li>\n<li>\nLocation: Virtual<\/p>\n<\/li>\n<li>\nWebcast Link: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FfAK4ioHxQNLX5A2utMmqiy%2FA8v8DKRP2kTsvfx76ytmjL&amp;esheet=54594888&amp;newsitemid=20260826612661&amp;lan=en-US&amp;anchor=TD+Cowen+6th+Annual+Novel+Mechanisms+in+Neuropsychiatry+Summit&amp;index=1&amp;md5=9234dfe0c6c8aa3f04a9cc73c8164ebb\">TD Cowen 6<sup>th<\/sup> Annual Novel Mechanisms in Neuropsychiatry Summit<br \/>\n<\/a><\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li><b>2026 Leerink Partners Biopharma Summit<\/b>\n<ul class=\"bwlistcircle\">\n<li>\nDates: Wednesday, September 23 &#8211; Friday, September 25, 2026<\/p>\n<\/li>\n<li>\nLocation: Healdsburg, CA<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\nAudio webcasts and replays of available presentations will be accessible on Definium\u2019s <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.definiumtx.com%2Fnews-events%2Fir-calendar&amp;esheet=54594888&amp;newsitemid=20260826612661&amp;lan=en-US&amp;anchor=Investor+Relations&amp;index=2&amp;md5=11b1662ed2b71410f2d86d57047da1d3\">Investor Relations<\/a> website for up to 90 days following each event.<\/p>\n<p><b>About Definium Therapeutics<\/b><\/p>\n<p>\nThe mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today\u2019s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX<\/p>\n<p>\nFor more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdefiniumtx.com%2F&amp;esheet=54594888&amp;newsitemid=20260826612661&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdefiniumtx.com%2F&amp;index=3&amp;md5=0e51c2d9f2c5296b117bbacbf20e578e\">https:\/\/definiumtx.com\/<\/a> and follow Definium Therapeutics on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Furl.us.m.mimecastprotect.com%2Fs%2FVlmTC82oMRF4jPoQH1h5Hy6_iR%3Fdomain%3Dinstagram.com%2F&amp;esheet=54594888&amp;newsitemid=20260826612661&amp;lan=en-US&amp;anchor=Instagram&amp;index=4&amp;md5=a4da14a6df27f34678ed99e6a2fc3ef0\">Instagram<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Furl.us.m.mimecastprotect.com%2Fs%2FwrNVC9rpDVI7mNGxU3iqHqBfl3%3Fdomain%3Dlinkedin.com&amp;esheet=54594888&amp;newsitemid=20260826612661&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=cc1541ecb9e3784d392082b667311f42\">LinkedIn<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Furl.us.m.mimecastprotect.com%2Fs%2F89p4C0R20JIP2g14fWsvH9IYFd%3Fdomain%3Dx.com&amp;esheet=54594888&amp;newsitemid=20260826612661&amp;lan=en-US&amp;anchor=X&amp;index=6&amp;md5=e7654a3d7bcba17e552d19c31fba8a03\">X<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260826612661r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260826612661\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260826612661\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Gitanjali Jain<br \/>\n<br \/>VP, Head of Investor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@definiumtx.com\">ir@definiumtx.com<br \/>\n<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:media@definiumtx.com\">media@definiumtx.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California New York United States North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research General Health Pharmaceutical Oncology Mental Health Clinical Trials Science Biotechnology Neurology Alternative Medicine Other Science Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260826612661\/en\/2882858\/3\/Definium_Logo_Therapeutics_Lockup_RGB_Black_Orange.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Definium Therapeutics to Participate at Upcoming Investor Conferences and Events NEW YORK&#8211;(BUSINESS WIRE)&#8211; Definium Therapeutics, Inc. (Nasdaq: DFTX) (&#8220;Definium&#8221; or the &#8220;Company&#8221;), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company\u2019s management team will participate in the following investor conferences and events: Stifel Hosted Webinar: Definium Therapeutics Virtual Fireside Chat Presentation Date and Time: Tuesday, September 1, 2026 at 1:00 PM ET Moderator: Paul Matteis, Head of Therapeutics Research Focus: Discussion of Definium\u2019s positive topline results from the Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder (GAD), including key clinical takeaways and implications for the program, as well &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Definium Therapeutics to Participate at Upcoming Investor Conferences and Events&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-998107","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Definium Therapeutics to Participate at Upcoming Investor Conferences and Events - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Definium Therapeutics to Participate at Upcoming Investor Conferences and Events - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Definium Therapeutics to Participate at Upcoming Investor Conferences and Events NEW YORK&#8211;(BUSINESS WIRE)&#8211; Definium Therapeutics, Inc. (Nasdaq: DFTX) (&#8220;Definium&#8221; or the &#8220;Company&#8221;), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company\u2019s management team will participate in the following investor conferences and events: Stifel Hosted Webinar: Definium Therapeutics Virtual Fireside Chat Presentation Date and Time: Tuesday, September 1, 2026 at 1:00 PM ET Moderator: Paul Matteis, Head of Therapeutics Research Focus: Discussion of Definium\u2019s positive topline results from the Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder (GAD), including key clinical takeaways and implications for the program, as well &hellip; Continue reading &quot;Definium Therapeutics to Participate at Upcoming Investor Conferences and Events&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-26T11:06:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260826612661r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Definium Therapeutics to Participate at Upcoming Investor Conferences and Events\",\"datePublished\":\"2026-08-26T11:06:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\\\/\"},\"wordCount\":403,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260826612661r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\\\/\",\"name\":\"Definium Therapeutics to Participate at Upcoming Investor Conferences and Events - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260826612661r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-08-26T11:06:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260826612661r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260826612661r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Definium Therapeutics to Participate at Upcoming Investor Conferences and Events\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Definium Therapeutics to Participate at Upcoming Investor Conferences and Events - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/","og_locale":"en_US","og_type":"article","og_title":"Definium Therapeutics to Participate at Upcoming Investor Conferences and Events - Market Newsdesk","og_description":"Definium Therapeutics to Participate at Upcoming Investor Conferences and Events NEW YORK&#8211;(BUSINESS WIRE)&#8211; Definium Therapeutics, Inc. (Nasdaq: DFTX) (&#8220;Definium&#8221; or the &#8220;Company&#8221;), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company\u2019s management team will participate in the following investor conferences and events: Stifel Hosted Webinar: Definium Therapeutics Virtual Fireside Chat Presentation Date and Time: Tuesday, September 1, 2026 at 1:00 PM ET Moderator: Paul Matteis, Head of Therapeutics Research Focus: Discussion of Definium\u2019s positive topline results from the Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder (GAD), including key clinical takeaways and implications for the program, as well &hellip; Continue reading \"Definium Therapeutics to Participate at Upcoming Investor Conferences and Events\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-26T11:06:14+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260826612661r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Definium Therapeutics to Participate at Upcoming Investor Conferences and Events","datePublished":"2026-08-26T11:06:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/"},"wordCount":403,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260826612661r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/","name":"Definium Therapeutics to Participate at Upcoming Investor Conferences and Events - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260826612661r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-08-26T11:06:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260826612661r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260826612661r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Definium Therapeutics to Participate at Upcoming Investor Conferences and Events"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/998107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=998107"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/998107\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=998107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=998107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=998107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}